DWA
IBRX icon

Dorsey Wright & Associates’s ImmunityBio IBRX Stock Holding History

Dorsey Wright & Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,668
Closed -$20K – 331
2020
Q2 		$20K Hold
1,668
– – ﹤0.01% 165
2020
Q1 		$5K Buy
+1,668
New +$8.35K ﹤0.01% 253

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Dorsey Wright & Associates's IBRX Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of ImmunityBio (IBRX) in Q3 2020, closing a stake of 1,668 shares — an estimated $20K sold.

Dorsey Wright & Associates first reported a position in IBRX in Q1 2020 and held it in 2 quarters. The position peaked at $20K in Q2 2020. 95 funds tracked by Wall St. Rank hold IBRX as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining ImmunityBio position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,668 ImmunityBio shares in Q3 2020, an estimated $20K.
  • Dorsey Wright & Associates first reported a position in ImmunityBio in Q1 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's ImmunityBio position peaked at $20K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.